Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by jammer4444on Nov 19, 2014 5:27pm
91 Views
Post# 23145610

Growth where it matters

Growth where it mattersCARA's sales in the UAE and India grew at annualized rates of 225% and 570% last quarter. If those rates continue for another year, those two countries will be contributing $1M/yr in sales.  The company has recenlty expanded into Turkey, Eastern Europe, Argentina, and Algeria, which will provide further growth.

CARDS is burning cash, but their customers are junior miners, who have been hit the hardest with the downturn in commodity prices.  The company needs to focus on marketing the product to majors who are the only ones still spending on exploration.

With a burn rate of $230k/mth, Diagnos has 6 months of cash, but the warrants will provide liquidity for an additional 2 years.  This gives lots of time for management to focus on commercializing CARA.  In the past, management has had to raise capital every year, which took away for their running of the business.

All the tools are in place for the company to grow exponentially.  We know CARA works, as evidenced by the successful field trials in the UAE.  The sales funnel is expanding with their entry into new markets.  Now we just have to sit back and watch the momentum build.
Bullboard Posts